A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation by Kamp, G.A. et al.
A Randomized Controlled Trial of Three Years Growth
Hormone and Gonadotropin-Releasing Hormone Agonist
Treatment in Children with Idiopathic Short Stature and
Intrauterine Growth Retardation*
G. A. KAMP, D. MUL, J. J. J. WAELKENS, M. JANSEN,
H. A. DELEMARRE-VAN DE WAAL, L. VERHOEVEN-WIND, M. FRO¨LICH,
W. OOSTDIJK, AND J. M. WIT
Department of Pediatrics, Leiden University Medical Center (G.A.K., W.O., J.M.W.), Sophia Children’s
Hospital Rotterdam, subdivision Endocrinology (D.M.), Catharina Hospital Eindhoven (J.J.J.W.),
University Medical Center Utrecht (M.J., L.V.-W.), Free University Hospital Amsterdam
(H.A.D.-v.d.W.), Department of Clinical Chemistry, and Leiden University
Medical Center (M.F.), The Netherlands
ABSTRACT
We assessed the effectiveness and safety of 3 yr combined GH and
GnRH agonist (GnRHa) treatment in a randomized controlled study
in children with idiopathic short stature (ISS) or intrauterine growth
retardation (IUGR). Gonadal suppression, GH reserve, and adrenal
development were assessed by hormone measurements in both
treated children and controls during the study period.
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8
ISS/4 IUGR), with a height SD score of 22 SD or less in early puberty
(girls, B2–3; boys, G2–3), were randomly assigned to treatment (n 5
18) with GH (genotropin 4 IU/m2 z day) and GnRHa (triptorelin, 3.75
mg/28 days) or no treatment (n 5 18). At the start of the study mean
(SD) age was 11.4 (0.56) or 12.2 (1.12) yr whereas bone age was 10.7
(0.87) or 10.9 (0.63) yrs in girls and boys, respectively.
During 3 yr of study height SD score for chronological age did not
change in both treated children and controls, whereas a decreased
rate of bone maturation after treatment was observed [mean (SD) 0.55
(0.21) ‘yr’/yr vs. 1.15 (0.37) ‘yr’/yr in controls, P , 0.001, girls and boys
together]. Height SD score for bone age and predicted adult height
increased significantly after 3 yr of treatment; compared with controls
the predicted adult height gain was 8.0 cm in girls and 10.4 cm in boys.
Furthermore, the ratio between sitting height/height SD score de-
creased significantly in treated children, whereas body mass index
was not influenced by treatment.
Puberty was effectively arrested in the treated children, as was
confirmed by physical examination and prepubertal testosterone and
estradiol levels. GH-dependent hormones including serum insulin-
like growth factor I and II, carboxy terminal propeptide of type I
collagen, amino terminal propeptide of type III collagen, alkaline
phosphatase, and osteocalcin were not different between treated chil-
dren and controls during the study period. Thus, a GH dose of 4 IU/m2
seems adequate for stabilization of the GH reserve and growth in
these GnRHa-treated children.
We conclude that 3 yr treatment with GnRHa was effective in
suppressing pubertal development and skeletal maturation, whereas
the addition of GH preserved growth velocity during treatment. This
resulted in a considerable gain in predicted adult height, without
demonstrable side effects. Final height results will provide the def-
inite answer on the effectiveness of this combined treatment. (J Clin
Endocrinol Metab 86: 2969–2975, 2001)
SINCE PUBERTY INITIATES the process of epiphysialfusion that determines final height, the first signs of
puberty are often perceived as an alarming signal in short
children (1), and the question whether therapeutic options
exist to improve final height is often asked. If initiated years
before the onset of puberty, GH treatment may have bene-
ficial effects on final height in children with idiopathic short
stature (ISS) and intrauterine growth retardation (IUGR) (2,
3). Once puberty has started, however, GH treatment in these
short children has limited value; GH may stimulate a rapid
progression through puberty, which is expected to reduce
the gain in final height (4–6). The addition of GnRH agonists
(GnRHa) to delay puberty has, therefore, been considered.
GnRHa were initially used in children with central preco-
cious puberty (CPP), with beneficial effects on adult height
(7–9). Recent trials with GnRHa in short children showed an
increment in adult height of 0.5–3.3 cm (10, 11). No controls
were included, except for one study with 4 yr treatment with
GnRHa vs. placebo, showing a height gain of 7.6 cm com-
pared with initial prediction in the GnRHa treated children
and of 10.3 cm compared with placebo group. The study
population, however, was very heterogeneous, and, there-
fore, the results are difficult to interpret (12). More recent
studies, using the combined treatment of GH and GnRHa in
children with ISS or IUGR, report a gain in final height
prediction between 20.5 to 10 cm (1, 13–17), but none of these
studies used randomized controls.
To answer the question whether GH and GnRHa treat-
ment may improve final height in pubertal children with ISS
and IUGR we designed a randomized controlled study with
3 yr treatment with combined GH and GnRHa treatment in
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24 girls and 12 boys with ISS or IUGR. We verified the
effectiveness of gonadal suppression by physical examina-
tions and by measurements of sex steroids in all children. To
assess the GH reserve during treatment, we yearly measured
insulin-like growth factor (IGF)-I, IGF-II, IGF-binding pro-
tein (BP)-3, and markers of collagen and bone metabolism, all
GH-dependent hormones (Kamp, G. A., A. H. Zwinderman,
J. van Doorn, W. Hackeng, M. Frolich, E. Scho¨nau, and J. M.
Wit, submitted for publication). Adrenal hormones were
measured to search for a possible effect of treatment on
adrenal development. Here, we present data obtained during
the first 3 yr of the study.
Patients and Methods
Forty children were randomized for either combined treatment with
GH and GnRHa or no treatment. GH (Genotropin, Pharmacia and Up-
john AB, Stockholm, Sweden) was given in a dose of 4 IU/m2 z day sc,
which is equivalent to 0.14 IU (0.05 mg)/kg body weight z day. GnRHa
[triptorelin (Decapeptyl, Ferring, Hoofddorp, The Netherlands); because
Decapeptyl was withdrawn by Ferring in 1998, we used the same prep-
aration from Ipsen] was given in a dose of 3.75 mg im every 28 days. The
randomization was performed separately in children with a known
history of IUGR, defined as a birth length # 22 sd score (18). Directly
after randomization, two patients randomized for treatment refused
treatment and two controls refused follow-up. Additionally, one ISS boy
and one IUGR girl, both controls, became drop-outs. We report 3-yr data
of 18 treated (12 ISS and 6 IUGR/6 boys and 12 girls) and 16 controls
(11 ISS and 5 IUGR/5 boys and 11 girls).
The protocol was reviewed and approved by the medical ethics
committees at the four participating centers [Catharina Hospital Eind-
hoven (n 5 12), Wilhelmina Childrens Hospital Utrecht (n 5 12), Free
University Hospital Amsterdam (n 5 10), and Sophia’s Childrens Hos-
pital Rotterdam (n 5 2)], and the parents of all children gave written
consent for the study. When appropriate, the consent of the children was
also obtained.
Inclusion criteria were G2 or G3 in boys (testicular volume of $4 and
#10 mL) and B2 or B3 in girls, an actual height # 22.0 sd score (19) or
between 21.0 and 22.0 sd score with a predicted adult height # 22.0
sd score [according to Bayley and Pinneau (20)], and a chronological age
and bone age less than 12 and 13 yr in girls and boys, respectively.
Furthermore, a maximum serum GH level .10 ug/L (1 ug 5 2 IU, The
First International Reference Preparation of hGH, MRC London, code
66/217 was used as standard) after provocation (exercise, arginine,
clonidine, l-dopa, or glucagon) and a normal ratio of sitting height/
subischial leg length (between P3 and P97) (21) were established. At the
time of inclusion, blood screening tests and urinanalysis were normal,
and none had evidence of malnutrition or hormonal or systemic disease.
All children were evaluated at baseline. Then, the children of the
treatment group were followed every 3 months during treatment and at
least once a year thereafter. Children in the control group were followed
on a yearly basis. Evaluations included measurements of height [mean
of four measurements was performed by the same observer (L.V.) at the
same hour of day on a Harpenden stadiometer], sitting height [mean of
two measurements (L.V.)], and weight. Pubertal staging was assessed by
one investigator (G.A.K.) in all children at all visits, according to the
method of Tanner. The Prader orchidometer was used to determine
testicular size in boys.
Height was expressed as sd score for chronological age (CA) and for
bone age (BA) according to Dutch references (19). Body mass index
(BMI) was calculated [weight/(height2)] and expressed as sd score (22).
Sitting height and sitting height/height were also expressed as sd score
(21). Target height was calculated (father’s height 1 mother’s height 1
or 2 12 cm for boys and girls, respectively)/2 13 cm (for the secular
trend) and expressed as sd score (19). BA radiographs were measured
yearly in all children and were determined according to the method of
Greulich and Pyle (23) by one independent investigator. To evaluate the
effect of treatment, we used the gain in predicted adult height (PAH),
defined as the difference between the height prediction at start and after
3 yr of treatment or follow-up. In girls, a yearly ultrasound of uterus and
ovaries was performed. We measured the volumes and examined the
occurrence of ovarian cysts.
Hormone analysis
Laboratory tests at baseline and at yearly visits included full blood
count, serum free T4, TSH, LH, FSH, estradiol in girls and testosterone
in boys, blood HbAlc, fasting blood glucose, serum fasting insulin, IGF-I,
IGF-II, IGFBP-3, leptin, DHEA, DHEAS, androstenedione, carboxy ter-
minal propeptide of type I collagen (PICP), amino terminal propeptide
of type III collagen (PIIINP), alkaline phosphatase, and osteocalcin.
Plasma levels of IGF-I, IGF-II, and IGFBP-3 were determined in one
assay in the endocrine laboratory of the Wilhelmina Children’s Hospital,
Utrecht, on samples that had been stored at 220 C for a maximum of
4 yr. These assays have been described previously (24). The levels of
IGF-I, IGF-II, and IGFBP-3 were expressed as ng/mL and compared with
references based on measurements in 906 healthy individuals. Smoothed
references for three plasma parameters and three ratios were constructed
using the LMS method (25). This method allows to find the best trans-
formation of data that lack a normal distribution (as do all these pa-
rameters), yielding a smoothed and statistically valid function. Serum
leptin (ng/mL) was measured by RIA (Linco Research Inc., St. Charles,
MO). PICP [normal range, 200–1000 ug/L (mean 6 2 sd), decreases with
age from 2–16 yr] and PIIINP [normal range, 5–18 ug/L (mean 6 2 sd),
decreases with age from 2–16 yr] were measured with RIA kits (Orion
Diagnostics, Helsinki, Finland). Serum alkaline phosphatase (IU/L) was
measured with the VITROS analyzer and osteocalcin [normal range,
1.8–6.6 ug/L (mean 6 2 sd)] with a RIA kit (DiaSorin, Inc., Stillwater).
Serum LH (IU/L) and FSH (IU/L) were performed with a solid phase,
time resolved immunofluorometric assay (Wallac, Inc., Turku, Finland).
Serum testosterone (nmol/L, in boys), DHEA (nmol/L), and andro-
stenedione (nmol/L) were measured with solid phase RIAs (Diagnostic
Products, Los Angeles, CA). Serum estradiol (pmol/L, in girls) was also
measured with a sensitive solid phase RIA (Orion, ESPO, Finland) and
DHEAS with an in-house developed RIA [Leiden, Department of Clin-
ical Chemistry (M.F.)]. All samples were measured in one assay on
samples that had been stored at 220 C for a maximum of 4 yr.
Statistics
Results are expressed as mean 6 sem or sd. The statistical analysis
comprised a paired t test for comparisons between data at baseline and
after 3 yr, and when appropriate for non-normal distribution we used
the Wilcoxon signed rank test. Differences between the treated children
and controls were tested by Student’s t test or Mann-Whitney tests.
Correlation analysis was performed appropriate for the distribution of
the variable. Changes in variables during the study period between
treated patients and controls were analyzed by repeated measurement
analysis. Reported are the changes in time between groups and changes
in time for both groups together.
Results
Auxology
Table 1 shows the auxological data at baseline and after 3
yr of study for ISS girls, ISS boys, IUGR girls, and IUGR boys
separately. There was no significantly different pattern be-
tween these four subgroups in changes in BA, height velocity
(HV), height sd score for CA, height sd score for BA, BMI sd
score, or in PAH in cm or sd score. Combined auxological
data of treated and control children are shown in Figs. 1–3
and in Table 2.
BA advanced significantly less in GH1GnRHa-treated
children compared with controls [0.55 (0.05) ‘yr’/yr vs. 1.15
(0.09) ‘yr’/yr, P , 0.001, all girls and boys together]. In
subgroups, a significant difference in BA was seen in treated
compared with control ISS boys after 3 yr of study (Table 1).
HV decreased significantly (P , 0.001) in the GH1GnRHa-
treated children from 7.0 (0.32) cm/yr during the first year
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of treatment to 5.4 (0.24) and 4.9 (0.30) cm/yr during the
second and third year, respectively. In the control group HV
was 7.4 (0.51), 7.0 (0.53) and 4.7 (0.4) cm/yr during the first,
second, and third year of study, respectively (third year HV
compared with the first year HV: P , 0.05). Height sd score
for CA did not change during 3 yr of study in all groups (see
Fig. 1A for GH1GnRHa vs. controls and Table 1 for sub-
groups). Height sd score for BA improved significantly in
GH1GnRHa-treated children compared with a decrease in
controls (P , 0.001, n 5 30, Fig. 1B). In subgroups, in ISS-
treated girls height sd score for BA was significantly different
between start of study and after 3 yr (Table 1).
The changes in PAH in cm or sd score were significantly
higher in GH1GnRHa-treated children compared with con-
trols (P , 0.001); the change in PAH sd score is shown in Fig.T
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FIG. 1. Height SD score for CA (A) and for BA (B) during the study
period. Height SD for CA does not change in time; height SD for BA
data show significant differences in time and between groups (P ,
0.001). C, Increase in PAH SD compared to the initial height predic-
tion. **, P , 0.05; @, P , 0.001.
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1C. The absolute values for changes in PAH (cm) between the
start of study and after 3 yr are summarized in Table 2. There
was no significant difference between ISS and IUGR children
or between boys and girls in change in PAH. In treated
children, age, BA, height sd score for CA, height sd score for
BA, BMI sd score, or pubertal stage at start of treatment,
IGF-I, IGF-II, IGFBP-3 at start of treatment, birth weight, or
target height sd score did not significantly correlate with the
change in PAH after 3 yr of treatment (univariate nonpara-
metric correlations).
BMI sd score did not change during the study period, in
both groups. There was a significant change in sitting height
sd score (P 5 0.05) and in the ratio sitting height to height sd
score (SHHt, P 5 0.016) in treated children compared with
controls. After 3 yr of study, SHHt changed 20.33 (0.77) sd
score in the treated group (having relatively longer legs after
3 yr of treatment) compared with 10.43 (0.83) sd score in
controls (Fig. 2).
Puberty
At the start of the study period no significant differences
were present between treated children and controls with
regard to Tanner stage. Pubertal development was effec-
tively arrested in the children treated with GH and GnRHa,
whereas puberty progressed in the control group. Figure 3
FIG. 2. Proportional growth during the study period, expressed as SD
score. A, Sitting Height SD: significant difference in time and between
groups (P , 0.01). B, Sitting Height/Height SD: significant difference
between groups (P , 0.05).
FIG. 3. Suppression of puberty during the study period. A, Tanner
breast stage in girls. B, Serum estradiol levels in girls. C, Mean
testicular volume in boys. D, Serum testosterone levels in boys. Sta-
tistical differences are not shown in this panel.
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shows the Tanner breast stage in relation to estradiol levels
in girls and the mean testicular volume in relation to testos-
terone levels in boys. Ultrasound evaluation of uterus vol-
ume and ovarian volumes in girls showed reduction in ovar-
ian volumes in the treated girls. We did not observe any
abnormalities in the ovaries (indicative for the development
of polycystic ovaries) or uterus by ultrasound in the children
on combined treatment.
Hormonal data
Serum free T4, TSH, blood HbAlc, fasting blood glucose,
and serum fasting insulin remained within the normal range
in all children during the study period. Figure 4 shows the
serum IGF-I, IGF-II, and IGFBP-3 levels (ng/mL) for treated
children and controls. Serum IGF-I and IGFBP-3 levels were
approximately 0 sd score, whereas serum IGF-II levels were
around 21 sd score. Serum IGF-I (ng/mL or sd score, or
IGF-II (ng/mL or sd score) were not different at start of study
or during 3 yr of follow-up between treated children and
controls, whereas IGFBP-3 (ng/mL or sd score) levels in
controls decreased significantly in comparison with treated
children during 3 yr of follow-up (P 5 0.01). With the ex-
ception of androstenedione, serum leptin, DHEA, DHEAS,
PICP, PIIINP, osteoalcin, and alkaline phosphatase levels
were also not different between treated and control children
during 3 yr of follow-up. All hormone levels increased
significantly with age in both treated and control children
(Table 3).
Serum leptin levels did not significantly differ between
controls and treated children. Pearson correlations between
BMI sd score and serum leptin levels showed no consistent
pattern: significant correlations were found at start and at 2
yr in girls (P , 0.05) and at 1 and at 3 yr in boys (P , 0.01).
Obesity defined as BMI sd score more than 2 was only
present in 1 boy in the GH1GnRHa group at one time point.
Discussion
Combined treatment with GH and GnRHa in short chil-
dren with ISS or IUGR in a randomized controlled trial
resulted in an unchanged height sd score for CA and a
decreased rate of bone maturation. Thus, height sd score for
BA and PAH increased significantly after 3 yr of treatment.
Compared with controls the predicted height gain was 8.0 cm
in girls and 10.4 cm in boys. Furthermore, body proportions
changed in favor of relatively longer legs in treated children,
and BMI was not influenced by treatment. This study is the
first randomized controlled trial in a relative large group of
children with ISS or IUGR. A placebo-controlled study with
3-month follow-up visits for both treated children and con-
trols would have been ideal to exclude all factors that could
have altered the results. However, for ethical reasons and to
keep the controls in the study, we chose yearly follow-ups
and no placebo injections in controls.
Previous studies using the combined treatment of GH and
GnRHa show considerable variability in gain of PAH, rang-
ing from 20.7 to 10.5 cm (1, 13, 14, 16, 17, 26). Results of two
of these studies seem comparable with our study (16, 26): the
gain in PAH of 9.3 cm in a group of seven girls reported by
Saggese et al. (27) was reduced to 6.3 cm after comparison
TABLE 2. Changes (mean 6 SEM) in PAH in cm between the
start and after 3 yr of study
No. Control GH 1 GnRHa
Girls 23 2.4 (1.69) 10.4 (1.24)
Boys 11 23.9 (2.09) 6.5 (0.87)
IUGR girls 7 0.3 (5.87) 11.1 (1.72)
ISS girls 16 3.1 (1.27) 10.1 (1.68)
IUGR boys 4 23.6 (2.40) 6.5 (0.30)
ISS boys 7 24.1 (4.50) 6.6 (1.58)
FIG. 4. IGF-I, IGF-II, and IGFBP3 levels during the study period
(mean 6 SD). A, IGF-I levels (ng/mL) increase significantly in both
groups during in time (P , 0.001). B, IGF-II levels (ng/mL). C,
IGFBP3 levels (ng/mL), showing a significant difference in time
(P , 0.001) and between groups (P 5 0.01).
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with a historical control group. The same pattern was ob-
served in our study in 23 girls, with a reduction of 10.4 to 8.0
cm when compared with randomized controls. Pasquino et
al. (16) also reported a gain of 10.5 cm in girls, but no controls
were included. A recent randomized controlled study of the
effect of the addition of GnRHa to GH treatment in seven
GH-deficient individuals showed a gain in near final height
of 1.4 sd score or 9 cm (27). After comparison with random-
ized controls the gain in PAH in our 11 boys increased from
6.5 to 10.4 cm. The decrease in height prediction in non-
treated short boys shows that this prediction method is over-
estimating final height in boys. This finding is in line with the
overestimation of final height in untreated ISS boys, as we
suggested earlier (28). Contrasting our expectations based on
findings from previous reports, a relative young BA or an
early pubertal stage were not predictive for a relative large
gain in adult height. This finding may have clinical appli-
cations for future treatment of older children in whom pu-
berty has progressed substantially. Thus, after 3 yr of study
our results are encouraging. However, the suggested gain in
final height is entirely based on the extent to which BA
advancement was delayed in the treated children and only
final height data will provide the definite answer on the
effectiveness if this combined treatment. The final height
gain may be probably less than 8 to 10 cm, as we have learned
from experience in previous studies in CPP (7).
The sitting height sd score and the ratio of sitting height
to height sd score decreased significantly in both treated girls
and treated boys during the study period. This indicates that
delaying puberty in our study has resulted in relatively
longer legs. This result is in accordance with the observation
in hypogonadotropic hypogonadism, who provide a natural
experiment of pubertal delay. These men also have relatively
longer legs compared with their trunk at final height (29). At
final height some change in body proportions may also be
present in treated children, but we expect that the trunk to
leg ratio will remain within the normal range. Our data on
body proportions are in contrast with the findings at near
final height in a recent study on GH-deficient children where
the addition of GnRHa resulted in no change in body pro-
portions (27).
The clinical observation that treatment with GnRHa may
lead to obesity could not be confirmed by changes in BMI sd
score or leptin levels in our study, even when data of boys
and girls were analyzed separately (30). Moreover, we could
not identify a consistent pattern between changes in BMI sd
score and changes in leptin. It has to be emphasized that a
BMI sd score change is not a good marker of change in fat
mass, particularly during puberty. Another explanation for
the absence of obesity in our treated children may be the
result of the combined treatment of GnRHa and GH we used.
The probable effect of GnRHa on induction of fat mass that
is usually reflected by increased leptin levels (31) may have
been counterbalanced by the anabolic effect of GH on muscle
mass in our treated children.
The therapeutic efficacy in terms of suppressing puberty
and the good compliance to treatment were shown by the
absence of progression of puberty at clinical assessments.
This was further confirmed at the biochemical level by pre-
pubertal levels of serum estradiol in girls and serum testos-
terone in boys during treatment. The development of poly-
cystic ovaries, a previously suggested side effect of GnRHa
treatment (P. Hindmarsh, personal communication), was not
observed in the ultrasound studies in our treated children.
The decreased growth rate after GnRHa treatment without
GH, as was observed in previous studies, may be explained
by a reduction of pituitary GH secretion after withdrawal of
sex steroids (32). The unchanged height sd score for CA after
treatment in our study suggests that the addition of GH
treatment seems to counteract this mechanism. Therefore,
the combined treatment resulted in preservation of growth
during treatment while a delay in bone maturation was ac-
complished. Assessments of IGF-I, IGF-II, IGFBP-3, PICP,
PIIINP, alkaline phosphatase, and osteocalcin suggest that a
GH dose of 4 IU/m2zday is needed for replacing the GH
secretion in puberty in these GnRHa-treated children. The
assumption that adrenal development is not altered by Gn-
RHa treatment was confirmed by the measurements of
DHEA and DHEAS. All androgens increased with age in
both groups. Androstenedione levels, however, increased
significantly less after 3 yr of study in treated children com-
pared with controls.
We conclude that 3 yr treatment with GnRHa was effective
in suppressing pubertal development, whereas the addition
of GH preserved the growth potential during treatment. This
resulted in a considerable gain in predicted adult height,
without demonstrable side effects. Final height results will
provide the definite answer on the effectiveness of this treat-
ment regimen.
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TABLE 3. Hormonal data (mean 6 SEM) at the start of study and after 3 yr for control and GH1GnRHa-treated children
Start After 3 yr Difference in time,
between groups
Difference in time,
whole groupControl Rx Control Rx
Leptin (ng/mL) 3.8 6 0.5 4.2 6 2.5 6.1 6 1.1 7.7 6 1.1 NS P , 0.001
DHEA (nmol/L) 4.9 6 0.7 7.3 6 1.2 10.3 6 3.7 13.1 6 5.9 NS P , 0.001
DHEAS (nmol/L) 1.7 6 0.3 1.7 6 0.3 2.7 6 1.3 3.2 6 0.3 NS P , 0.001
Androstenedione (nmol/L) 1.5 6 0.1 2.2 6 0.4 2.9 6 0.7 2.8 6 0.3 P 5 0.01 P , 0.001
PICP (ug/L) 275.4 6 22.0 321.5 6 30.6 251.3 6 40.5 272.2 6 14.7 NS P , 0.01
PIIINP (ug/L) 8.8 6 0.8 9.0 6 0.7 8.1 6 0.8 10.0 6 0.8 NS P 5 0.01
Osteocalcin (ug/L) 5.8 6 0.7 5.8 6 0.6 7.9 6 1.2 8.1 6 0.7 NS P , 0.01
Alkaline phosphatase (IU/L) 250.3 6 17.0 210.2 6 10.4 179.5 6 23.6 183.4 6 21.9 NS P , 0.01
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